![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.395 | -8.31% | 4.36 | 4.35 | 4.69 | 4.75 | 4.36 | 4.75 | 143,012 | 08:44:49 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.50 | 9.58M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/5/2020 07:42 | So delay till July but looks like the home trial will be relatively quick. Interesting read across in the issue with getting trialists. I wouldn't want to be in a company without a trial already started or near completion. | ![]() waterloo01 | |
26/5/2020 07:39 | Looks like they're combining data from the hospital and home trial too on reading the 2nd rns | ![]() d1nga | |
26/5/2020 07:31 | COPD as well, three sets of data this summer.Looking like July/August for all this data. The recruitment has obviously set them back with the data moving from June to July. I note they have labelled the hospital as Late and Home trials as early. Hedging their bets? | ![]() crookie3634 | |
26/5/2020 07:30 | Hospital trial nearly fully recruited, plus an extra earlier stage trial... 98 of 100 recruited for the hospital trial Another 120 over 50s to be recruited for home trial earlier in the disease | ![]() bountyhunter | |
26/5/2020 07:25 | That RNS reads even better ! | ![]() amaretto1 | |
26/5/2020 07:18 | Will play a critical role against the fight against COVID !!!He's basically saying it works ...Boris bit interesting in Paper.. | ![]() amaretto1 | |
26/5/2020 07:17 | And... In the other RNS about results today we have: Supply chain in the event of success In the event that the current trials prove successful, Synairgen has made good progress with suppliers to scale up production of SNG001 rapidly with the aim of being able to supply meaningful quantities by the end of this year. LOXL2 inhibitor programme Pharmaxis, the Company's Australian-based partner for the antifibrotic LOXL2 inhibitor programme, has updated the market (on 30 April 2020) stating that it is currently pursuing a number of different partnering options with international pharma companies to enable this drug to enter the clinic in phase 2 trials and will provide more information when the process concludes. Synairgen is entitled to receive circa 17% of Pharmaxis' licence receipts/royalties, net of allowable expenses. | ![]() lauders | |
26/5/2020 07:16 | https://www.soundhea | slinkyj | |
26/5/2020 07:15 | Looks like they are happpy with results from the hospitalsWith out saying too muchThey know it's working ... | ![]() amaretto1 | |
26/5/2020 07:09 | I was completely wrong about the timing of the hospital trial though. It must have got very difficult to recruit patients towards the end, which is fair enough I guess. | ![]() nobbygnome | |
26/5/2020 07:05 | Anyway, for now the question is "Will there be some news in around 10 minutes or not?". Tick tock. Happy the answer is "YES"! | ![]() lauders | |
26/5/2020 06:54 | https://www.pressrea | slinkyj | |
26/5/2020 06:53 | i don't care what others say....Use your commonsense i was in hospital 4 months .. believe me ... nothing goes unnoticed or gossiped about :-) | ![]() amaretto1 | |
26/5/2020 06:52 | Yes dreadful journalism but great to see that the home trial is in the papers. Some good PR at last! | ![]() nobbygnome | |
26/5/2020 06:48 | Not if Nobby and our other more industry familiar experts here are correct amaretto1. It has been drummed into me whenever someone suggests what you are suggesting. We will find out in due course. Anyway, for now the question is "Will there be some news in around 10 minutes or not?". Tick tock. | ![]() lauders | |
26/5/2020 06:22 | Don't you think family and nurses would already know if they were emerging quicker and healthier than others patients ..It would be impossible to keep this information under wrapsWe all know it works, it's to what extent ....That's what the final results are for ! | ![]() amaretto1 | |
26/5/2020 05:54 | However, the validity of the article comes into question when you read this part: Those who went through the previous clinical trial in hospital have already reported positive results. Hmm.. Are they talking about the one we are awaiting results for and nobody will know the answers until it is unblinded? | ![]() lauders | |
26/5/2020 05:50 | 'He said: "We can stop people from having that bad second week'. | ![]() myst1 | |
26/5/2020 05:39 | Thanks for that link dated 25th May s120896! BRITISH scientists have developed a new coronavirus inhaler which could help to fight the bug as soon as early symptoms appear. Researchers from the University of Southampton have sent 120 inhalers out to Covid-19 patients for a home trial beginning today. Perhaps I actually got my timing right for once on Friday? | ![]() lauders | |
26/5/2020 01:40 | Hi all, expect and RNS Tuesday morning. hxxps://www.the-sun. | ![]() s120896 | |
26/5/2020 00:52 | Good, fairly large article in Tuesdays Daily Mail should give the share price a boost today. Mainly talking about the at home trial. | ![]() blueflame | |
25/5/2020 20:55 | Strangely they don’t have control of whether the results are good or bad and not that much control of the timing! | ![]() nobbygnome | |
25/5/2020 20:23 | Be better to come with good results ahead of deadline rather than bad ones late. Who knows. | ![]() dealer55 | |
25/5/2020 20:11 | What a nice few days off. Just got a Google alert on the below. Expecting a strong week prepared for a stale one! Feel like I could use an Christmas Advent Calendar waiting down for the sack of cash hopefully coming soon haha! | ![]() adman50 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions